Antigenics (OTCPK:ANTI) - Stock Price, News & Analysis

ANTI Stock Overview

A clinical-stage biopharmaceutical company, discovers, manufactures, and develops immunotherapies for cancer. More details

ANTI fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Shares are highly illiquid

Has not reported any financial data

Does not have a meaningful market cap ($45)

Antigenics, Inc. Competitors

DermTech

OTCPK:DMTK.Q

US$35.0

eFFECTOR Therapeutics

OTCPK:EFTR

US$940.0

MJ Holdings

OTCPK:MJNE

US$58.0

Genocea Biosciences

OTCPK:GNCA.Q

US$5.9k

Price History & Performance

Summary of all time highs, changes and price drops for Antigenics
Historical stock prices
Current Share Price	US$0.000001
52 Week High	US$0.000001
52 Week Low	US$0.000001
Beta	0
11 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	-99.00%
5 Year Change	n/a
Change since IPO	-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	ANTI	US Biotechs	US Market
7D	0%	4.3%	1.6%
1Y	n/a	18.8%	32.3%

Return vs Industry: Insufficient data to determine how ANTI performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how ANTI performed against the US Market.

Price Volatility

Is ANTI's price volatile compared to industry and market?
ANTI volatility
ANTI Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

Stable Share Price: ANTI's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine ANTI's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1994	n/a	n/a	agenusbio.com

Antigenics, Inc., a clinical-stage biopharmaceutical company, discovers, manufactures, and develops immunotherapies for cancer. The company was founded in 1994 and is based in Lexington, Massachusetts.

Antigenics, Inc. Fundamentals Summary

How do Antigenics's earnings and revenue compare to its market cap?
ANTI fundamental statistics
Market cap	US$45.00
Earnings (TTM)	US$0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is ANTI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ANTI income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$0
Earnings	US$0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did ANTI perform over the long term?

See historical performance and comparison